Gastrointestinal Cancer

Tremelimumab plus durvalumab sustained an overall survival improvement in unresectable hepatocellular carcinoma.

The addition of retifanlimab to carboplatin and paclitaxel prolonged PFS for patients with chemotherapy-naive recurrent or metastatic SCAC.

First-line combinations with trastuzumab deruxtecan showed initial efficacy in HER2-positive esophageal, gastric, and gastroesophageal junction cancers.

First-line IMM-1-104 combined with modified gemcitabine/nab-paclitaxel elicited both partial and complete responses in patients with pancreatic cancer.

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.

ABD-147 has received orphan drug designation from the FDA for use in patients with neuroendocrine carcinoma.

Certepetide has been granted orphan drug designation by the FDA for the treatment of patients with cholangiocarcinoma.

Jennifer R. Eads, MD, explains the relevance of negative results from the ECOG-ACRIN EA2174 trial in esophageal/gastroesophageal junction adenocarcinoma.

The supplemental new drug application for fruquintinib plus paclitaxel in second-line gastric cancer in China has been voluntarily withdrawn.

Chih-Yi Liao, MD, discusses the value of molecular testing in biliary tract carcinoma.

Anthony B. El-Khoueiry, MD, discusses immune suppression in advanced hepatocellular carcinoma post-checkpoint inhibitor therapy.

Craig E. Devoe, MD, MS, discusses next steps for assessing the ELI-002 7P vaccine in patients with MRD–positive, KRAS-mutant PDAC and CRC.

Ciara Kelly, MBBCh, BAO, discusses ongoing trials to further enhance the treatment of patients with gastrointestinal stromal tumor.

Ciara Kelly, MBBCh, BAO, discusses the evaluation of DCC-3116 in combination with ripretinib in advanced gastrointestinal stromal tumor.

The FDA has accepted a supplemental biologics license application for nivolumab plus ipilimumab for first-line unresectable hepatocellular carcinoma.

Ciara Kelly, MBBCh, BAO, discusses the importance of genetic abnormality testing for patients with gastrointestinal stromal tumors.

The FDA has granted orphan drug designation to PT217 for the treatment of patients with neuroendocrine carcinoma.

Ryan Hood, BA, discusses a study investigating the association between BRCA1/2 pathogenic variants and primary tumor location in pancreatic cancer.

The acceleration of targeted therapy drug development has led investigators to home in on RAS mutations as agents are approved in colorectal cancer.

Trastuzumab deruxtecan earned conditional approval in China for HER2-positive gastric/gastroesophageal junction cancer after at least 2 lines of therapy.

Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy plus chemotherapy has improved the durability of outcomes in advanced GI cancers.

Samuel Cytryn, MD, and David B. Zhen, MD, on factors for selecting nivolumab plus chemotherapy or ipilimumab in esophageal squamous cell carcinoma.

Samuel Cytryn, MD, and David B. Zhen, MD, on long-term data for nivolumab plus chemotherapy or ipilimumab in advanced esophageal squamous cell carcinoma.

Samuel Cytryn, MD, and David B. Zhen, MD, discuss findings from a Q-TWiST analysis of the CheckMate 649 trial in advanced gastric/GEJ cancer.

Samuel Cytryn, MD, and David B. Zhen, MD, on 4-year data from CheckMate 649 for nivolumab plus chemotherapy in first-line advanced gastric/GEJ cancer.